Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSosandar Regulatory News (SOS)

Share Price Information for Sosandar (SOS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.00
Bid: 10.50
Ask: 11.50
Change: -0.125 (-1.12%)
Spread: 1.00 (9.524%)
Open: 11.125
High: 11.125
Low: 11.00
Prev. Close: 11.125
SOS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

18 Dec 2006 07:05

Embargoed: 0705hrs 18 December 2006

MeDaVinci plc ("MeDaVinci" or the "Company") Interim Results for the Six Months ended 30 September 2006

Chairman's Statement

I present the results for the six months to 30 September 2006 reflecting a period in which the Company has been largely inactive, with the exception of its sole investment in ErgoDynamics Applications BV (19.2%), made in March of this year shortly before the financial year end of the Company.

Financial Results

The Company has reported a loss on ordinary activities before taxation of ‚£ 30,000 on nil turnover resulting in a diluted loss per share of 0.4 pence. Fixed assets from investments stand at ‚£597,000 with cash at bank and in hand at the six month period end of ‚£236,000.

Review of Portfolio Companies

ErgoDynamics Applications BV (19.2%)

ErgoDynamics has developed a proprietary and patented system for the prevention and relief of lower back pain. Since the investment by MeDaVinci in March 2006, ErgoDynamics has begun the commercialisation of its back pain prevention and relief technology in The Netherlands in the office environment. So far it has successfully completed pilot programs with over fifty corporate, institutional and governmental employers. Last September ErgoDynamics introduced the system in the professional transportation market, providing chairs for bus and truck drivers, at the IAA exhibition in Hanover, Germany.

Outlook

The Company announced today its development as an active investment company focussed on innovative technologies, products and services in the Health and Wellness markets. For this reason the Company changed its name from HHK Plc to MeDaVinci plc in October to reflect its new direction. I am delighted to welcome to the Board our new Chief Executive, Rob Westerhof, who, as the former CEO of Philips Asia, Philips Medical Systems and Philips North America, will spearhead the implementation of our strategy and the building of our investment portfolio. Rob has invested ‚£1,000,000 into the Company today along with a further ‚£740,757 raised from new and existing investors.

It is envisaged that the type of investments that MeDaVinci will consider will include University spin-offs and the financing of inventions and entrepreneurs who have exciting products or concepts but the lack of capital or know-how to commercialise them. The Company will consider only those situations where it will be the (joint) lead investor and where it will place a MeDaVinci representative on the board of the portfolio company. Potential portfolio companies should display one or a number of the following characteristics: a distinctive or innovative market position, intellectual property or patents, niche expertise, a limited time to market (i.e. do not require extensive regulatory body approval) and a clear exit scenario. From his 35 years within the Philips organisation Rob Westerhof, along with myself and my fellow executive directors, have access to a large number of opportunities that are considered initially too small or early-stage by the major medical companies but which, through access to growth capital, contacts and expert guidance, may be progressed to the level at which they become attractive acquisition targets, cash generators or suitable for IPO.

A number of such investments are already under consideration by the Board and I look forward to announcing developments in those areas to you in the near future.

Peter TeerlinkChairman15 December 2006

For further information please contact,

Peter Teerlink, ChairmanMeDaVinci plcTel. +31 10 288 4343Ben SimonsHansard GroupTel. +44 (0)20 7245 1100PROFIT AND LOSS ACCOUNTFOR THE SIX MONTHS ENDED 30 SEPTEMBER 2006 Unaudited Unaudited Audited 6 months 2 March 2005 2 March 2005 to 30 to to September 30 September 31 March 2006 2005 2006 Notes ‚£'000 ‚£'000 ‚£'000 Turnover - - - Cost of Sales (-) (-) (-) Gross profit - - - Administrative expenses (37) (6) (340) Operating loss (37) (6) (340) Other interest receivable 7 8 14 (Loss)/profit on ordinary 30 2 (326)activities before taxation Taxation on loss on ordinary - - -activities (Loss)/profit for the financial (30) 2 (326)year attributable to members of the parent company Loss per share: basic 2 (0.4p) 0.3p (4.1p) : diluted (0.4p) 0.02p (4.1p)

There are no recognised gains or losses other than the profit for the period.

BALANCE SHEETAS AT 30 SEPTEMBER 2006 Unaudited Unaudited Audited 30 30 September September 31 March 2006 2005 2006 Notes ‚£'000 ‚£'000 ‚£'000 Fixed assets Investments 3 597 - 597 _________ 597 - 597 _________ Current assets Debtors - 3 - Cash at bank and in hand 236 339 334 _________ 236 342 334 Creditors: amounts falling due (32) (1) (100)within one year _________ Net current assets 204 341 234 _________ Net assets 801 341 831 Capital and reserves Called up share capital 136 82 136 Share premium reserve 743 257 743 Warrant reserve 278 - 278 Profit and loss account (356) 2 (326) _________ Total shareholders' funds 4 801 341 831

The interim financial report was approved by the board of directors on 15 December 2006 and was signed on their behalf by:

P TeerlinkDirectorCASH FLOW STATEMENTFOR THE SIX MONTHS ENDED 30 SEPTEMBER 2006 Notes Unaudited Unaudited Audited 6 months 2 March 2 March to 2005 to 30 2005 to September September 31 March 2006 2005 2006 ‚£'000 ‚£'000 ‚£'000 mot Cash outflow/(inflow) from 5 (105) (8) 38operating activities Returns on investment and servicing of finance Interest received 7 8 14 Capital expenditure and financial investment Payments to acquire investments - - (57) __________ Net cash outflow before financing (98) - (5) Financing Issue of shares - 410 410 Cost of issue - (71) (71) __________ - 339 339 __________ (Decrease)/Increase in cash (98) 339 334 NOTES TO THE INTERIM REPORTFOR THE PERIOD ENDED 30 SEPTEMBER 2006

1. ACCOUNTING POLICIES

i. Basis of preparation

The interim report for the period ended 30 September 2006 and 2005 is unaudited and does not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. It has been prepared under the historical cost convention and on a basis consistent with the accounting policies for the period ended 31 March 2006. The results for the year ended 31 March 2006 and the balance sheet of that date are an extract from the statutory financial statements for that year, which have been filed with the Registrar of Companies and on which the company's auditors gave an unqualified report and did not contain a statement under Section 237 (2) or (3) of that Act.

(ii) Investments

A certain investment within the company's investment fund falls within the definition of associated undertakings, as defined by FRS 9 "Associates and Joint Ventures". However the directors consider that Medavinci Plc does not exert significant influence as defined in FRS 9 and so the investment has not been equity accounted for.

2. EARNINGS PER SHARE

The calculation of basic and diluted earnings per share is based on loss of ‚£ 30,000 for the 6 months ended 30 September 2006 (31 March 2006: loss of ‚£ 326,000, 30 September 2005: profit of ‚£2,000), and on the weighted average number of ordinary shares in the period of 7,891,623 (31 March 2006: 7,891,623, 30 September 2005: 7,400,000; diluted 11,883,569).

3. INVESTMENTS

a. Non Subsidiary Undertakings

Unaudited Unaudited Audited 30 September 30 September 31 March 2006 2005 2006 ‚£'000 ‚£'000 ‚£'000 Shares Brought forward 597 - - Additions - - 597 Carried forward 597 - 597Company Holding Value of Investments % ‚£'000 HLJ Participations BV 25.6% 557 Medavinci Development BV 5.0% 40

4. RECONCILIATION OF MOVEMENT IN EQUITY SHAREHOLDERS' FUNDS

Unaudited Unaudited Audited 6 months 2 March 2 March ended 30 2005 to 30 2005 to September September 31 March 2006 2005 2006 ‚£'000 ‚£'000 ‚£'000 Group (Loss)/profit for the period (30) 2 (326) On issue of shares - 82 136 Premium on issued of shares - 257 743 Share warrant charge - - 278 Increase in shareholders' funds (30) 341 831 Opening shareholders' funds 831 - - Closing shareholders' funds 801 341 831

5. RECONCILIATION OF OPERATING LOSS TO NET CASH OUTFLOW FROM

OPERATING ACTIVITIES Unaudited Unaudited Audited 6 months 2 March 2 March ended 30 2005 to 30 2005 to September September 31 March 2006 2005 2006 ‚£'000 ‚£'000 ‚£'000 Operating loss (37) (6) (340) (Increase)/decrease in operating debtors - (3) 265and prepayments (Decrease)/increase in operating (68) 1 100creditors and accruals Increase in equity share warrant charge - - 278 Cash (outflow)/inflow from operating (105) (8) 38

activities

MEDAVINCI PLC
Date   Source Headline
11th Jul 20187:00 amRNSFinal Results
29th Jun 20187:00 amRNSDirector Appointment
16th May 20187:00 amRNSTrading Update
17th Apr 20187:00 amRNSSosandar to present at the UK Investor Show
11th Apr 20183:41 pmRNSHolding(s) in Company
29th Mar 20187:00 amRNSInterim Results
12th Feb 20187:00 amRNSTrading Update
21st Dec 20177:00 amRNSChange of Accounting Year End
15th Dec 201711:09 amRNSHolding(s) in Company
15th Dec 201711:08 amRNSHolding(s) in Company
11th Dec 20177:00 amRNSTrading Update
20th Nov 20179:08 amRNSHolding(s) in Company
17th Nov 20174:02 pmRNSHolding(s) in Company
6th Nov 20175:18 pmRNSHolding(s) in Company
6th Nov 201710:29 amRNSHolding(s) in Company
3rd Nov 20174:03 pmRNSDirector/PDMR Shareholding
2nd Nov 20177:00 amRNSFirst Day of Dealings
1st Nov 20171:16 pmRNSResult of Meeting
17th Oct 20172:41 pmRNSFurther Loan to Thread 35 Limited
11th Oct 20178:00 amRNSSch 1 - Orogen Plc (to be renamed Sosandar Plc)
10th Oct 20174:12 pmRNSProposed Acquisition and Notice of General Meeting
22nd Sep 20177:00 amRNSHalf-year Report
8th Aug 201712:37 pmRNSFurther Drawdown of Loan to Thread 35 Limited
28th Jul 201710:23 amRNSResult of AGM
6th Jul 201711:45 amRNSFurther re Drawdown of Loan
6th Jul 201711:30 amRNSNotice of AGM
29th Jun 20177:00 amRNSFinal Results
14th Jun 20177:00 amRNSDrawdown of Loan to Thread 35 Limited
26th May 20177:30 amRNSSuspension - Orogen Plc
26th May 20177:00 amRNSSuspension, Loan and Potential Acquisition
3rd May 201711:04 amRNSIssue of Equity
26th Apr 20179:01 amRNSHolding(s) in Company
18th Apr 201710:53 amRNSHolding(s) in Company
10th Apr 20174:52 pmRNSDirector/PDMR Shareholding
10th Apr 20172:20 pmRNSDirector/PDMR Shareholding
7th Apr 20171:11 pmRNSResult of Meeting
21st Mar 20177:00 amRNSProposed Placing and Open Offer
9th Jan 20177:00 amRNSSilverton Project Drilling Results
14th Dec 20167:00 amRNSMutsk Drilling Further Extends Gold Zone
29th Nov 20167:00 amRNSMutsk Drilling Extends Project To Over 1 kilometre
9th Nov 201611:30 amRNSResult of General Meeting
8th Nov 20167:00 amRNSStep-out Drilling Extends Mutsk Gold Zone
28th Oct 20167:00 amRNSMutsk Update
19th Oct 20167:00 amRNSNotice of GM
18th Oct 20167:00 amRNSStep-Out Drilling To Commence At Mutsk
13th Oct 201612:00 pmRNSDrilling To Commence At Silverton
28th Sep 20167:00 amRNSHalf-year Report
6th Sep 20167:00 amRNSMutsk Gold Mineralisation Substantially Extended
31st Aug 20167:00 amRNSMutsk gold project Armenia
8th Aug 20167:00 amRNSMutsk Drilling Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.